Dendritic cells coinjected with @entity5 cells treated with an anticancer drug to induce XXXX rejection.

@entity19 @entity5 @entity1138 @entity60 @entity1139 @entity694
PURPOSE: We examined whether bone marrow-derived dendritic cells (DCs) could induce antitumor immunity when a chemotherapeutic drug was added. METHODS: CT26 (a @entity19 @entity694 cell line syngeneic with BALB/c) and CT26-bearing @entity19 were treated with @entity1138 ( @entity1139 ) intraperitoneally (i.p.). Next, @entity19 immunized with a coinjection of DCs and @entity1139 -treated CT26 (i.p.) were given an intradermal inoculation of CT26. Finally, CT26-bearing @entity19 were treated with @entity1139 (i.p.) with or without DCs, given peritumorally. RESULTS: Although the inoculated @entity5 was not rejected in the control @entity19 , CT26 was rejected in 50% of the @entity19 injected with @entity1139 alone. Apoptosis was observed in the @entity1139 -treated CT26 cells in vitro and in vivo. Immunization with DCs and apoptotic CT26 cells, but not with apoptotic CT26 alone, gave protection against @entity5 challenge in 7 of 13 @entity19 . A significantly higher level of cytotoxic T-cell activity and @entity60 production was seen in the protected @entity19 . When @entity1139 (i.p.) treatment was followed by peritumoral DC injection in the CT26-bearing @entity19 , remarkable therapeutic effects were observed. CONCLUSION: DCs can collaborate with chemotherapy-induced @entity5 cells and elicit improved antitumor immunity, probably through the acquisition of @entity5 -associated antigens from @entity5 cells.
